Viyash Scientific Limited · NSE:VIYASH
Viyash Scientific — SeQuent Scientific — Shareholder Meeting (August 2019)
23 slides from Viyash Scientific's shareholder meeting presentation, Aug 29, 2019
Slide 1: Warm Welcome to Shareholders
Warm Welcome to Shareholders August 29, 2019
Slide 2: Agenda
AGENDA Strategic Performance Key Initiatives Agenda Decision and in FY19 for FY20 of AGM Actions 2
Slide 3: Strategic Decisions and Actions
STRATEGIC DECISIONS AND ACTIONS 3
Slide 4: Competitive Edge: Scaled-up capabilities
Competitive Edge Scaled-up capabilities
Slide 5: Scaled-up capabilities
Scaled-up capabilities • Acquired Bremer Pharma in Germany • Global footprints with 8 world class • Formulations: 1,000+ Animal health manufacturing facilities dosages across 12 dosage forms • Addition of EUGMP injectable facility • Established presence in France & Italy, in Germany two key EU marke
Slide 6: Strengthening manufacturing footprints to drive growth
Strengthening manufacturing footprints to drive growth Addition of EUGMP injectable Addition of EUGMP API facility in Germany facility in India Complements our current manufacturing at Vizag (USFDA approved) and Tarapur (Intermediates) Bremer Pharma acquisition will help to boost Comprehensive API m
Slide 7: Broadbased portfolio, Differentiated solutions
Broadbased portfolio Differentiated solutions 7
Slide 8: Formulations
Formulations Leading revenue driver 1,000+ 80 35+ 50%+ Registrations Countries with Launches Sales to regulated marketing presence markets 7,145 6,307 Key Highlights Robust growth across geographies, driven by 35+ launches and improved market share Revenues in ₹ Mn across key geographies Lack of cla
Slide 9: APIs: Scaling the capability curve
APIs Scaling the capability curve 26 3 1.9x 2.4x Commercial APIs Manufacturing Asset Turn Growth with top-5 facilities customers 3,248 Key Highlights 2,188 Accelerated momentum in the US with second product commercialisation Revenues in ₹ Mn Highest filings among generic animal health companies in t
Slide 10: Scaling value curve
Scaling value curve US filed / EU-CEP 5 US and 3 CEP filings during the year API Pipeline approved approvals 14 17 10 Pipe Line of 35+ products Expanded R&D team in India, adept to Formulations execute 10+ projects per annum 20+ new filings in US in next 3 years Developed capabilities to execute 2 1
Slide 11: Performance in FY19
Sequent & >) Proven Ability In Life Sciences. aLivira PERFORMANCE IN FY19
Slide 12: Strong performance across businesses
Strong performance across businesses Revenue Distribution FY19 FY18 YoY% Europe, 51% Formulations 7,145 6,307 13.3% Europe 3,664 3,168 15.7% Formulations, API, 31% Turkey 962 1,160 (17.1%) 69% Emerging Emerging Markets 1,583 1,163 36.1% Markets, 22% LATAM 937 816 14.8% Turkey, 14% APIs 3,248 2,188 4
Slide 13: Results at a glance
Results at a glance FY2019 YOY FY19 10,393 Revenues 22% FY18 8,495 FY19 1,327 Board recommends a dividend EBITDA 52% of ₹0.2 per equity share (10%) FY18 871 FY19 570 PAT 5.6x FY18 102 13
Slide 14: Delivering consistent outcome
Delivering consistent outcome All values in ₹ Mn Revenue Revenue 2,819 2,517 2,705 2,352 2,090 2,249 2,328 1,943 1,975 2,003 1,700 10,393 1,097 8,495 6,890 Q1 Q2 Q3 Q4 FY17 FY18 FY19 EBITDA EBITDA 12.7% 13.1% 12.8% 14.3% 10.6% 10.0% 13.2% 9.6% 9.5% 10.3% 1327 11.2% 7.6% 8.4% 6.2% 5.2% 355 402 250 32
Slide 15: Consolidated Financials
Consolidated Financials FY19 FY19 FY18 All values in ₹ Mn PARTICULARS Audited Audited Audited Revenue from Operations 10,393 10,401 8,494 Material Consumption (5,430) (5,455) (4,625) Gross Margin 4,963 4,945 3,870 % 47.8% 47.5% 45.6% Operating Expenses (3,635) (3,625) (2,999) EBITDA 1,327 1,320 871
Slide 16: Key Balance Sheet items
Key Balance Sheet items All values in ₹ Mn ROCE Net debt to EBITDA Particulars Mar-19 Mar-18 3.75 15.1% 11.8% 2.81 Shareholders' funds 7,067 6,476 7.8% 1.84 1.52 2.9% Minority Interest 403 370 FY17 FY18 FY19 FY19 Q4* FY17 FY18 FY19 FY19 Q4* Net Borrowings 2,452 2,451 *Quarter Annualised Highlights I
Slide 17: Key Initiatives in FY20
Sequent & >) Proven Ability In Life Sciences. aLivira KEY INITIATIVES IN FY20
Slide 18: Key events - FY20
Key events - FY20 ▪ 1st formulations filing in US, largest veterinary market in the world Advancing Ambitions ▪ Establish leadership in the US ▪ Launch of Alivira Italy operations, key European Union market Global reach ▪ Launched 18 products globally ▪ 3x capacity expansion at Bremer, provide thrus
Slide 19: Q1 FY20 performance
Q1 FY20 performance All values in ₹ Mn Sales Movement EBITDA Movement 2,780 385 18.2% 54..2% 2,352 250 Q1FY19 Q1FY20 Q1FY19 Q1FY20 19
Slide 20: Creating value for all stake-holders
Creating value for all stake-holders Delivered on Expectations FY20 Outlook 1Q FY20 status ▪ High-teen ▪ Revenue up 18% revenue growth ▪ EBITDA expansion ▪ 200+ bps margin 330 bps YoY expansion 20
Slide 21: Agenda
Sequent & >) Proven Ability In Life Sciences ativira AGENDA
Slide 22: Agenda Items - Thirty Fourth Annual General Meeting
Agenda Items - Thirty Fourth Annual General Meeting Ordinary Business Special Business Remuneration to cost auditor for the financial year Adoption of consolidated and standalone financial 2019-20 statement of the Company for the financial year ended 31 March 2019 Re-appointment of Dr. Kausalya Sant
Slide 23: Thank You
Sequent | & Ability In Life Sci Thank You
SeQuent Scientific — Shareholder Meeting (August 2019) on 6ix